v3.26.3
Segment Reporting and Disaggregation of Relevant Expense Captions (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information
The following table presents information about reported significant segment expenses and net loss (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Research and development (1):
Azenosertib external development costs$11,436 $12,602 $51,663 $33,153 
Unallocated research and development expenses and discontinued programs10,898 10,348 34,550 44,654 
Total research and development22,334 22,950 86,213 77,807 
General and administrative 8,820 10,784 27,187 29,812 
Other (2)
2,339 7,043 6,947 5,775 
Net loss
$(28,815)$(26,691)$(106,453)$(101,844)
Adjustments for cash used in operations:
Non-cash expenses3,216 898 9,659 15,281 
Changes in working capital(7,108)(1,170)(6,105)(7,744)
Cash used in operations:$(32,707)$(26,963)$(102,899)$(94,307)

(1) The Company tracks external development costs by product candidate or development program, but does not allocate personnel costs, general license payments made under our licensing arrangements or other internal costs to specific development programs or product candidates. These costs are included in unallocated research and development expenses and discontinued programs.
(2) Other consists of investment and other income, net, restructuring charges and income tax expense.